SK Bioscience Co

SK Bioscience Co Net Debt/FCF

The Net Debt to Free Cash Flow Ratio of SK Bioscience Co (302440.KS) as of Nov 3, 2026 is -2.94. In the previous year, Net Debt to Free Cash Flow Ratio was -1.28 — a change of 130.57% (lower).

Net Debt/FCF

-2.94

YoY

130.57%

Last updated:

Net Debt to Free Cash Flow Ratio of SK Bioscience Co is 2025 -2.94 . Net Debt to Free Cash Flow Ratio of SK Bioscience Co was 2024 -1.28 . It decreases by 130.57% lower compared to the previous year.

The SK Bioscience Co Net Debt/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/FCF
Date
Net Debt/FCF
Jan 1, 2018
14.64 KRW
Jan 1, 2019
-54.30 KRW
Jan 1, 2020
0.93 KRW
Jan 1, 2021
0.07 KRW
Jan 1, 2024
-1.28 KRW
Jan 1, 2025
-2.94 KRW
The SK Bioscience Co Net Debt/FCF history
YEARNet Debt/FCFYoY
-2.94+130.57%
-1.28-1,875.37%
0.07-92.24%
0.93-101.71%
-54.30-470.86%
14.64—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SK Bioscience Co Stock analysis

What does SK Bioscience Co do? SK Bioscience Co Ltd is a South Korean biotechnology company headquartered in Seongnam, Gyeonggi-Do. The company went public on March 18, 2021, with its stock listed on the Korean Stock Exchange under the ticker 302440.KS. It operates within the health care sector, specifically in the biotechnology industry. SK Bioscience employs 1,067 people and focuses on the development and distribution of bio and vaccine products. The company distributes its products both domestically and internationally. While specific product names are mentioned in unverified sources, the company is known to be involved in the production of vaccines and infusion solutions. It also engages in technology export business, though detailed information about its technology or export markets is not provided. The company's website is https://www.skbioscience.co.kr/, where further information about its operations and products may be available. SK Bioscience does not disclose specific details about its product lines beyond the general categories of vaccines and infusion solutions, and it does not provide information on acquisitions, founding year, or key personnel. The company's activities are centered around biotechnology and healthcare, with a focus on vaccine development and distribution. Its market presence spans both domestic and international markets, though specific regions or countries are not specified. The company's financial data, including revenue and market capitalization, is not included in the provided information. SK Bioscience is a publicly traded company with a focus on biotechnology and healthcare innovation. SK Bioscience Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SK Bioscience Co stock

Net Debt to Free Cash Flow Ratio of SK Bioscience Co is -2.94 in 2025.

Net Debt to Free Cash Flow Ratio of SK Bioscience Co changed from -1.28 to -2.94, representing a 130.57% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Free Cash Flow Ratio SK Bioscience Co since 2006 – with annual values, charts, and detailed analysis.

Net Debt/FCF indicates how many years it would take to repay net debt using free cash flow. Lower ratios suggest faster deleveraging potential.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Free Cash Flow Ratio's SK Bioscience Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — SK Bioscience Co

All Key Metrics — SK Bioscience Co